<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01937182</url>
  </required_header>
  <id_info>
    <org_study_id>2013-002253-30</org_study_id>
    <nct_id>NCT01937182</nct_id>
  </id_info>
  <brief_title>The Efficacy of Citalopram Treatment in Acute Stroke</brief_title>
  <acronym>TALOS</acronym>
  <official_title>The Efficacy of Citalopram Treatment in Acute Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danish Council for Independent Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Danish Regions Medicine Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We wish to conduct a prospective, randomized, double blind, placebo controlled multi center
      study of the combined neuroprotective and antithrombotic effects of SSRI treatment after
      stroke.

      Hypotheses:

      SSRI treatment commenced in the acute phase of stroke (day 0-7) protects against new
      thromboembolic events and leads to better rehabilitation. 600 stroke patients will be
      randomized in a 1:1 ratio.

      The treatment and follow up period is 6 months. During these 6 months there will be 2
      clinical follow up visits, one telephone control and one visit to evaluate compliance
      regarding medication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design TALOS is an investigator-initiated, national multicenter randomized- and
      placebo-controlled, double blind trial testing citalopram in acute ischemic stroke.

      Randomization Eligible patients will be randomized 1:1 to treatment with either citalopram or
      placebo. Treatment allocation is double-blinded based on computer-generated algorithm via a
      dedicated website. Patients whose treatment is stopped within 31 days after inclusion will be
      replaced.

      Intervention and follow-up Patients randomized to citalopram will receive oral treatment with
      20 mg tablets (10 mg if age ≥65 and/or reduced liver function) for 6 months with telephone
      contact after 2 weeks and 3 months and follow-up visits at 1 and 6 months. If patients
      develop depression dosage is initially doubled, followed by an additional control to evaluate
      effect and, if necessary, shifted to open-label antidepressant treatment. After 6 months,
      treatment will either stop or switch to open-label antidepressants at the discretion of the
      investigator.

      Substudy 120 of patients will begin treatment within 12 hours after treatment with
      recombinant tissue plasminogen activator. These patients will receive a standard acute
      magnetic resonance imaging (MRI) with additional perfusion and angio sequences. The 24-hour
      control scan will be done using MRI instead of conventional CT.

      Data monitoring When 300 patients have been included in the trial, an interim analysis will
      be performed. The unblinded results of this analysis will be reviewed by an independent data
      monitoring committee.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2013</start_date>
  <completion_date type="Actual">December 19, 2016</completion_date>
  <primary_completion_date type="Actual">December 19, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vascular death, Transient Ischemic Attack (TIA)/stroke and myocardial infarction (combined)</measure>
    <time_frame>6 months</time_frame>
    <description>Myocardial Infarction: STEMI (ST segment elevation myocardial infarction) and NSTEMI (non-ST segment elevation myocardial infarction)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional status at 6-months</measure>
    <time_frame>6 months</time_frame>
    <description>Functional status at 6-months, measured by the modified Rankin Scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vascular death</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death of any cause</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TIA/stroke</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>6 months</time_frame>
    <description>Using the Global Utilization Of Streptokinase And Tpa For Occluded Arteries definition for bleeding (GUSTO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>6 months</time_frame>
    <description>STEMI (ST segment elevation myocardial infarction) and NSTEMI (non-ST segment elevation myocardial infarction)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability/dependence</measure>
    <time_frame>6 months</time_frame>
    <description>Using the modified Rankin Scale and the Barthel Index (BI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical activity</measure>
    <time_frame>6 months</time_frame>
    <description>Using the Physical Activity Scale for the Elderly (PASE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive and organic cerebral impairment</measure>
    <time_frame>6 months</time_frame>
    <description>Using the Mini-Mental State Examination and the Symbol Digit Modalities Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>6 months</time_frame>
    <description>Using the Multidimensional Fatigue Inventory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-stroke depression</measure>
    <time_frame>6 months</time_frame>
    <description>Using the Major Depression Inventory test (MDI), Global depression scale (self and clinician and Hamilton Depression Scale - 6 item (HAM-D6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological Crying</measure>
    <time_frame>6 months</time_frame>
    <description>Using the Pathological Crying Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion size</measure>
    <time_frame>6 months</time_frame>
    <description>Using FLAIR positive lesion size on MRI 24 hours after treatment with Alteplase</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">642</enrollment>
  <condition>Stroke, Ischemic</condition>
  <arm_group>
    <arm_group_label>Selective Serotonin Reuptake Inhibitors</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention Drug: Citalopram</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intervention Drug: Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citalopram</intervention_name>
    <description>Citalopram 10-40 mg per day administered orally</description>
    <arm_group_label>Selective Serotonin Reuptake Inhibitors</arm_group_label>
    <other_name>Selective Serotonin Reuptake Inhibitors</other_name>
    <other_name>SSRI</other_name>
    <other_name>Seropram®</other_name>
    <other_name>Cipramil®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1/2-2 tablets per day with no intrinsic drug activity</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>inactive drug</other_name>
    <other_name>inactive medicine</other_name>
    <other_name>inactive substance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  First ever ischemic stroke

          -  Age 18 years or above

        Exclusion Criteria:

          -  Hemorrhagic stroke

          -  Dementia or other neurodegenerative disease

          -  Antidepressant medical treatment within 6 months of admission

          -  Acute need for antidepressant treatment

          -  Drug abuse or other conditions that may indicate noncompliant behavior

          -  Liver failure (increased liver enzyme levels up to or more than 2 times upper limit)

          -  Renal failure (eGFR below 30 ml/min per 1.73m2)

          -  Hyponatremia (S-potassium below 130 mmol/l)

          -  Actively bleeding ulcer

          -  Fatal stroke or other severe co-morbidity that markedly decreases expected life span

          -  Prolonged corrected QT-interval (QTc above 480 ms)

          -  Ongoing treatment with drugs known to prolong the QTc interval
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grethe Andersen, DSMc</last_name>
    <role>Study Chair</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kristian L Kraglund, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Boris Modrau, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aalborg Universitetshospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helle Iversen, DSMc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Glostrup University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aalborg University Hospital, Department of Neurology</name>
      <address>
        <city>Aalborg</city>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital, Department of Neurology</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glostrup University Hospital, Department of Neurology</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>https://www.researchgate.net/project/The-Efficacy-of-Citalopram-Treatment-in-Acute-Stroke-TALOS</url>
    <description>Researchgate</description>
  </link>
  <link>
    <url>http://www.strokecenter.org/trials/clinicalstudies/the-efficacy-of-citalopram-treatment-in-acute-stroke</url>
    <description>Strokecenter.org</description>
  </link>
  <link>
    <url>https://dk.linkedin.com/in/kristian-kraglund-888b1631</url>
    <description>LinkedIn</description>
  </link>
  <reference>
    <citation>Siepmann T, Penzlin AI, Kepplinger J, Illigens BM, Weidner K, Reichmann H, Barlinn K. Selective serotonin reuptake inhibitors to improve outcome in acute ischemic stroke: possible mechanisms and clinical evidence. Brain Behav. 2015 Sep 23;5(10):e00373. doi: 10.1002/brb3.373. eCollection 2015 Oct. Review.</citation>
    <PMID>26516608</PMID>
  </reference>
  <reference>
    <citation>Bonaventura A, Liberale L, Vecchié A, Casula M, Carbone F, Dallegri F, Montecucco F. Update on Inflammatory Biomarkers and Treatments in Ischemic Stroke. Int J Mol Sci. 2016 Nov 25;17(12). pii: E1967. Review.</citation>
    <PMID>27898011</PMID>
  </reference>
  <reference>
    <citation>Mortensen JK, Johnsen SP, Larsson H, Andersen G. Early Antidepressant Treatment and All-Cause 30-Day Mortality in Patients with Ischemic Stroke. Cerebrovasc Dis. 2015;40(1-2):81-90. doi: 10.1159/000435819. Epub 2015 Jul 11.</citation>
    <PMID>26184925</PMID>
  </reference>
  <reference>
    <citation>Adelborg K, Sundbøll J, Videbech P, Grove EL. The Risk of Thromboembolism in Users of Antidepressants and Antipsychotics. Adv Exp Med Biol. 2017;906:351-361. Review.</citation>
    <PMID>27638627</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2013</study_first_submitted>
  <study_first_submitted_qc>September 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2013</study_first_posted>
  <last_update_submitted>February 23, 2017</last_update_submitted>
  <last_update_submitted_qc>February 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>SSRI (Selective Serotonin Reuptake Inhibitors)</keyword>
  <keyword>Serotonin</keyword>
  <keyword>5-HT (5-Hydroxytryptamine)</keyword>
  <keyword>Neuroprotection</keyword>
  <keyword>MRI (Magnetic Resonance Imaging)</keyword>
  <keyword>Platelet</keyword>
  <keyword>CT (computerized tomography)</keyword>
  <keyword>Post Stroke Depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Serotonin</mesh_term>
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
    <mesh_term>Serotonin Uptake Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

